Sanofi-Regeneron’s Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) announced results from a Phase 3 open-label extension trial of Dupixent (dupilumab) as maintenance therapy…